S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Europe bans Russian diesel, other oil products over Ukraine
Biden's State of the Union to tout policy wins on economy
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
How will EU ban and West's price cap on Russian diesel work?
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Evacuations urged in Ohio town as train wreck smolders
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:VCEL

Vericel - VCEL Stock Forecast, Price & News

$31.06
-0.28 (-0.89%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.46
$31.73
50-Day Range
$21.09
$31.34
52-Week Range
$17.30
$43.97
Volume
388,739 shs
Average Volume
422,663 shs
Market Capitalization
$1.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00

Vericel MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
19.1% Upside
$37.00 Price Target
Short Interest
Bearish
12.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Vericel in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$1.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.46) to ($0.18) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.38 out of 5 stars

Medical Sector

962nd out of 1,025 stocks

Biological Products, Except Diagnostic Industry

159th out of 168 stocks

VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

Vericel (NASDAQ:VCEL) Downgraded to Sell at StockNews.com
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
HC Wainwright Reiterates Buy Rating for Vericel (NASDAQ:VCEL)
Vericel (NASDAQ:VCEL) Lifted to "Hold" at StockNews.com
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Vericel Third Quarter 2022 Earnings: Misses Expectations
Vericel Reports Third Quarter 2022 Financial Results
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Company Calendar

Last Earnings
11/09/2022
Today
2/05/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+19.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-7,470,000.00
Pretax Margin
-11.55%

Debt

Sales & Book Value

Annual Sales
$156.18 million
Book Value
$3.64 per share

Miscellaneous

Free Float
44,767,000
Market Cap
$1.47 billion
Optionable
Optionable
Beta
1.72

Social Links


Key Executives

  • Dominick C. Colangelo
    President, Chief Executive Officer & Director
  • Michael HalpinMichael Halpin
    Chief Operating Officer
  • Joseph A. Mara
    Chief Financial Officer & Treasurer
  • Jonathan Mark HopperJonathan Mark Hopper
    Chief Medical Officer
  • Sean C. FlynnSean C. Flynn
    Secretary, Senior Vice President & General Counsel













VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2023?

5 brokers have issued 12 month price objectives for Vericel's shares. Their VCEL share price forecasts range from $29.00 to $45.00. On average, they predict the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 19.1% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2023?

Vericel's stock was trading at $26.34 at the beginning of the year. Since then, VCEL shares have increased by 17.9% and is now trading at $31.06.
View the best growth stocks for 2023 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) released its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02. The biotechnology company earned $38.55 million during the quarter, compared to analysts' expectations of $40.02 million. Vericel had a negative trailing twelve-month return on equity of 10.41% and a negative net margin of 11.36%.

What guidance has Vericel issued on next quarter's earnings?

Vericel updated its FY 2022 earnings guidance on Saturday, January, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $164.00 million-$165.00 million, compared to the consensus revenue estimate of $164.62 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (4.97%), Fisher Asset Management LLC (3.73%), New York State Common Retirement Fund (2.19%), Scout Investments Inc. (0.72%), Comerica Bank (0.49%) and Allspring Global Investments Holdings LLC (0.34%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $31.06.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.47 billion and generates $156.18 million in revenue each year. The biotechnology company earns $-7,470,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Vericel have?

The company employs 281 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 2/5/2023 by MarketBeat.com Staff